期刊文献+

236例弥漫大B细胞淋巴瘤患者临床特点及预后因素分析 被引量:10

原文传递
导出
摘要 弥漫大B细胞淋巴瘤(DLBCL)是中老年人群中最常见的一种侵袭性非霍奇金淋巴瘤(NHL),通过联合化疗后有近半数以上的患者可长期存活,但仍有相当一部分患者因淋巴瘤进展而死亡。如何进一步评估DLBCL患者的预后,以及采用生物学分型和制定个体化治疗方案是当前研究的热点之一。DLBCL的临床预后评估目前仍采用国际预后指数(IPI),
出处 《中华血液学杂志》 CAS CSCD 北大核心 2012年第9期768-770,共3页 Chinese Journal of Hematology
  • 相关文献

参考文献14

  • 1Cheson BD, Homing SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin' s lym- phomasc. NCI Sponsored International Working Group. J Clin On- col, 1999, 17:1244.
  • 2Hans CP,Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immu- nohistochemistry using a tissue microarray. Blood, 2004, 103 : 275 -282.
  • 3Coiffier B. Non-Hodgkin' s lymphomas. In:Cavalli F, Hansen HH, Kaye SB, eds. Textbook of medical oncology. London : Martin Dun- itz, 1997:265-287.
  • 4A predictive model for aggressive non-Hodgkin' s lymphoma. The International Non-Hodgkin' s Lymphoma Prognostic Factors Pro-ject. N Engl J Med, 1993, 329:987-994.
  • 5Effect of age on the characteristics and clinical behavior of non- Hodgkin' s lymphoma patients. The Non-Hodgkin' s Lymphoma Classification Project. Ann Onco1,1997,8:973-978.
  • 6Gutierrez-Garcia G, Colomo L,Villamor N, et at. Clinico-biological characterization and outcome of primary nodal and extranodal dif- fuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma, 2010, 51:1225-1232.
  • 7王晶,克晓燕,赵灵芝,李敏,景红梅,王继军,赵伟,高子芬.74例弥漫大B细胞淋巴瘤的预后相关因素分析[J].中华血液学杂志,2007,28(10):667-670. 被引量:17
  • 8Sehn LH, Berry B, Chhanabhai M, et al. The revised Internation- al Prognostic Index (R-IPI) is a better predictor of outcome than standard IPI for patients with diffuse large B-cell Lymphoma treated with R-CHOP. Blood, 2007, 109:1857-1861.
  • 9Alizadeh AA,Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403:503-511.
  • 10Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large cell lymphoma. N Engl J Med, 2002, 346 : 1937-1947.

二级参考文献11

  • 1王苗,李敏,韩志惠,高子芬.胃肠道黏膜相关淋巴组织淋巴瘤BCL-10的表达[J].中华血液学杂志,2004,25(10):592-595. 被引量:1
  • 2闵大六,夏海龙,周晓燕,孙孟红,杨文涛,张太明,郑爱华,施达仁.弥漫大B细胞淋巴瘤组织bcl-6蛋白表达及基因重排[J].中华病理学杂志,2005,34(6):327-331. 被引量:4
  • 3翁阳,高子芬,刘侃,张伟京,克小燕,李敏.弥漫性大B细胞淋巴瘤预后相关因素的研究[J].中华内科杂志,2005,44(9):681-683. 被引量:10
  • 4Zhang A, Ohshima K, Kikuchi M, et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Int, 1999, 49:1043-1052.
  • 5Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403:503-511.
  • 6Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 2002, 346:1937-1947.
  • 7Shipp MA, Ross KN, Golub TR. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med, 2002, 8:68-74.
  • 8Hans CP, Weisenburger DD, Chan WC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004,103:275-282.
  • 9Chang CC, McClintock S, Perkins SL, et al expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol, 2004, 28:464-470.
  • 10Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood, 2002, 99:1136-1143.

共引文献16

同被引文献87

  • 1李京京,顼晋昆,李莉.EB病毒阳性的扁桃体溃疡临床特征分析[J].山东大学耳鼻喉眼学报,2020,34(1):58-62. 被引量:1
  • 2崔旭,邓长安,刘霆,孟文彤,徐才刚,粟军.血管内大B细胞淋巴瘤1例报告并文献复习[J].临床血液学杂志,2005,18(3):161-163. 被引量:8
  • 3钟艳平,杨华,王连有,刘学娟.儿童扁桃体原发性恶性B细胞淋巴瘤临床病理观察[J].诊断病理学杂志,2005,12(5):350-352. 被引量:3
  • 4周立强,孙燕,谭文勇,李陶,王琦路,冯凤仪,王金万,储大同,石远凯,李晔雄,孙云田,吕宁.非霍奇金淋巴瘤1125例临床病理分析[J].癌症进展,2006,4(5):391-397. 被引量:47
  • 5Shiramizu B, Goldman S, Kusao I, et al. Minimal disease assess- ment in the treatment of children and adolescents with intermediate-risk ( Stage 111/IV ) B-cell non-Hodgkin lymphoma: a children's oncology group report. Br J Haematol, 2011, 153: 758-763.
  • 6Alfred R, Wolfram K. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol, 2008, 142: 329-347.
  • 7Murphy SB. Classification, staging and end resuhs of treatment of childhood non-Hodgkin' s lymphomas: dissimilarities from lympho- mas in adults. Semin Oncol, 1980,7: 332-339.
  • 8Cheson B, Pfistner B, Juweid M, et al. Revised reponse criteria for malignant lymphoma. J Clin Oncol, 2007,25 : 579-586.
  • 9Catherine P, Anne A, Mary G, et al. Results of the randomizedinternational FAB/LMB96 trial for intermediate risk B-cell non- Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood, 2007, 109 : 2773-2780.
  • 10Oschlies I, Burkhardt B, Salaverria I, et al. Clinical, pathologi- cal and genetic features of primary mediastinal large B-cell lympho- mas and mediastinal gray zone lymphomas in children. Haemato- logica, 2011,96: 262-268.

引证文献10

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部